"The new Snowden-Pencer laparoscopic scissors are very modular, so we can adjust a tray as we see fit to create a very cost-effective approach to our surgeries," said Dr. Ryan Tyner, a bariatric surgeon at Lovelace Westside Hospital in Albuquerque and Fellow of the American College of Surgeons. "I prefer to use the best instruments for my patients, and my personal opinion is that this is the best line on the market."
That should make CFN shareholders smile with the same level of enthusiasm as the company's many product representatives. I also learned that for more than 50 years, Snowden-Pencer instruments from CareFusion have offered the medical community exceptional levels of performance and longevity.
This harkens back to the days when CFN was a division of Cardinal Health (CAH), which spun CareFusion off in 2009. CAH is a stock to watch. This $108 billion company headquartered in Dublin, Ohio, is in the business of improving the cost-effectiveness of health care in general. It also pays a 2.4% dividend!
Back to CFN: The company also makes and develops market-leading technologies including infusion pumps, automated dispensing systems, ventilation and respiratory products, and services for data-mining surveillance. It has an extensive line of critically needed "interventional medicine" products.In the company's own words, "No patient, procedure or physician is the same, which is why CareFusion offers a full range of clinically relevant product choices for interventional procedures. Our products and services for interventional procedures are designed to meet individual patient needs and help physicians deliver positive clinical outcomes using minimally invasive and percutaneous techniques. "As an innovator in interventional medicine technologies, CareFusion offers unique products in a growing number of areas, including drainage, vertebral augmentation, biopsy and other diagnostic procedures." With such a diverse portfolio no wonder its profits are outstanding! Below is the kind of one-year chart an investor likes to see, both price-wise as well as CFN's trailing-twelve-month operating margin. It's almost picture perfect and when you take into consideration its most recent quarter's year-over-year earnings growth of 13.7%, you can see why the market likes CFN. CFN data by YCharts
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts